A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
By targeting toxic protein clumps in the brain, Dr. Martin Tolar, founder-CEO of Alzheon, aims to outsmart Alzheimer’s decades ahead of symptoms - and reshape global neurology.
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
As drugmakers face mounting complexity and cost in clinical trials, Saama’s AI-driven platform promises swifter, more precise results.
Allucent is a new CRO with a new CEO on a mission to support young biotechs.
SpyGlass Pharma is poised to revolutionize glaucoma treatment by implanting an innovative long-term drug delivery system directly inside the eye. Their treatment promises to continuously release eyedrop medication for 3 years after surgery, as opposed to using eye drops manually every day.
Guardant Health has seen a string of consistent firsts - most recently FDA approval for colorectal cancer in July, 2024
GERD affects 65 million Americans, yet innovation in treatment had stagnated. Phathom Pharmaceuticals' FDA approval of VOQUEZNA® (vonoprazan) is a big moment for patients.
If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope.
“I think I'm blessed with truly the best team in all of pharma… we are doing something that's bigger than all of us!”
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”
"One of our first patients was treated over five years ago. He had received 109 injections over 10 years, and five years after a single Ixo-Vec injection, he is free of injections with stable vision and no fluid in the eye."
CAR T-cell therapies are often lauded as one of the industry’s most important frontiers, and these therapies have seen amazing success in treating hematological cancers — will autoimmune diseases yield next?
Seer's Proteograph Product and Analysis suites are utilizing proprietary nanoparticle technology to help us understand diseases like never before. David Horn, President and CFO, tells us more.
Foghorn Therapeutics recently announced dosing of the first patient in the Phase 1 trial of FHD-909 in collaboration with Eli Lilly.
The CEO of Cellares sits down to tell us how the Cell Shuttle, an engineering marvel of 21st Century biotech, was invented and the lives that it could save...
